Medicinova
Presença
Medicinova é uma empresa listada sob o símbolo MNOV (US).
Executivos
Veja o organograma con seus 8 executivos principais
Biografias mais buscadas da Medicinova
- Yuichi Iwaki, Director, President and Chief Executive Officer
- Hideki Nagao, Director
- Jeff Himawan, Chairman of the Board
Criar um alerta
para seguir os movimentos de executivos da Medicinova.
Biotecnologia
Medicinova possui 2.295 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Johnson & Johnson has announced the acquisition of Proteologix (publicado em 20 de maio de 2024).
- Rapport Therapeutics acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 20 de maio de 2024).
- Lycia Therapeutics acaba de anunciar uma arrecadação de fundos de 107 milhões de dólares. (publicado em 15 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Medicinova
- MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology | MediciNova, Inc.
- MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada | MediciNova, Inc.
- MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria | MediciNova, Inc.
- MediciNova Receives Gene Therapy Milestone Payment | MediciNova, Inc.
- MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury | MediciNova, Inc.
- MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe | MediciNova, Inc.
- MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe | MediciNova, Inc.
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology | MediciNova, Inc.
- MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe | MediciNova, Inc.
- MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting | MediciNova, Inc.
- View more press releases Close
Redes sociais sobre Medicinova
- Medicinova na Wikipedia, Google News e Yahoo Finance
- Medicinova na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Yuichi Iwaki 
Ligue para a Medicinova em +1 858...
